Neon Therapeutics, which is developing a targeted immunotherapy platform for various cancers, raised $100 million by offering 6.25 million shares at $16, within the range of $15 to $17. Insiders had indicated on purchasing up to $35 million of the IPO (35%).
Neon Therapeutics plans to list on the Nasdaq under the symbol NTGN. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as lead managers on the deal.
